| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 4, Issue 12 957-964, Copyright © 1993 by American Association of Cancer Research
ARTICLES |
RB Roden, Y Shachar-Hill, SC Cosulich, TR Hesketh and JC Metcalfe
Department of Biochemistry, University of Cambridge, United Kingdom.
The role of p21c-ras in the activation of DNA synthesis in quiescent Swiss 3T3 fibroblasts was examined by scrape loading or microinjecting the neutralizing monoclonal antibody Y13-259 into the cells. Y13-259 delayed but did not block both the serum-stimulated entry of the cells into S phase and the accumulation of cdc2 mRNA and protein at the G1-S boundary. Introduction of Y13-259 also stimulated expression of sufficient p21c-ras to neutralize the loaded antibody; this finding suggests that the delay of S phase is attributable to the time taken to synthesize an excess of p21c-ras over the antibody and implies autoregulation of c-ras expression. Y13-259 had no effect upon phosphoinositide-mediated responses ([Ca2+]i increase and activation of protein kinase C) to platelet-derived growth factor or bombesin, demonstrating that p21c-ras is not required for mitogen activation of protein kinase C. Y13-259 inhibited 5-bromo-2'-deoxyuridine incorporation in response to all of the combinations of mitogens used to stimulate quiescent cells (fetal calf serum, platelet-derived growth factor, and the combination of insulin with 12-O-tetradecanoylphorbol-13-acetate, bombesin, epidermal growth factor, or prostaglandin E1), indicating that p21c-ras functions on pathways common to all of the effective combinations of mitogens examined.
This article has been cited by other articles:
![]() |
D. G. Woodside and B. W. McIntyre Inhibition of CD28/CD3-Mediated Costimulation of Naive and Memory Human T Lymphocytes by Intracellular Incorporation of Polyclonal Antibodies Specific for the Activator Protein-1 Transcriptional Complex J. Immunol., July 15, 1998; 161(2): 649 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Malcolm, C. M. Elliott, and J. H. Exton Evidence for Rho-mediated Agonist Stimulation of Phospholipase D in Rat1 Fibroblasts. EFFECTS OF CLOSTRIDIUM BOTULINUM J. Biol. Chem., May 31, 1996; 271(22): 13135 - 13139. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |